Clinical Trial: Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition: Coronavirus Infections
Study Type: Observational [Patient Registry]
Official Title: Prospective Monitoring of BNT162b2 Second Vaccination Booster for Prevention of the COVID-19 Infection in Health Care Workers (HCW)
Brief Summary:
The SARS-CoV-2 virus causes severe respiratory illness and is an ongoing global pandemic. On December 12, 2020 the FDA approved Pfizer's BioNTech vaccine BNT162b2 which is a messenger RNA type of vaccine for use. This vaccine has shown in numerous studies the ability to induce a strong immune response and provide both humeral and cellular protection against wild type, alpha and delta variants of SARS-CoV2 virus.In Israel the national vaccine operation began in mid-December 2020 which included 2 initial doses three…
Read more